---
title: "Eli Lilly: 80% of patients using Omvo achieved long-term relief. At the one-year mark of the Phase 3"
description: "Eli Lilly: 80% of patients using Omvo achieved long-term relief. At the one-year mark of the Phase 3 LUCENT-2 study, 78% of patients achieved clinical remission without the use of corticosteroids"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260149476.md"
published_at: "2025-10-07T10:47:01.000Z"
---

# Eli Lilly: 80% of patients using Omvo achieved long-term relief. At the one-year mark of the Phase 3

> Eli Lilly: 80% of patients using Omvo achieved long-term relief. At the one-year mark of the Phase 3 LUCENT-2 study, 78% of patients achieved clinical remission without the use of corticosteroids

Eli Lilly: 80% of patients using Omvo achieved long-term relief. In the Phase 3 LUCENT-2 study, 78% of patients achieved clinical remission without the need for corticosteroids at the one-year mark

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| 礼来在冬奥会广告中赞美科学和体育的进步 | 礼来正在推出一项新的企业活动 “Never Over”，与 2026 年意大利冬季奥运会相结合。该活动包括一则长达一分钟的电视广告，展示了档案资料和讨论科学方法的旁白。它强调了礼来对科学进步的承诺与奥运运动员的奉献之间的联系。该活动旨在突出 | [Link](https://longbridge.com/en/news/275193934.md) |
| 礼来公司声明：Mirikizumab 在中国获批用于治疗中度至重度克罗恩病和溃疡性结肠炎 | 礼来：Mirikizumab 在中国获得批准用于治疗中重度克罗恩病和溃疡性结肠炎 - 公司声明 | [Link](https://longbridge.com/en/news/275551012.md) |
| 美股盘前热门交易：礼来盘前跌 4.71%；Nebius 盘前跌 4.48% | 礼来盘前跌 4.71%；Nebius 盘前跌 4.48%；凯利服务-B 盘前涨 399.91%；AIM ImmunoTech 盘前涨 45.97%；TransCode Therapeutics 盘前涨 41.44%。 | [Link](https://longbridge.com/en/news/274987815.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.